New pill takes on advanced cancers in first human test

NCT ID NCT07629258

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will take the pill by mouth and be closely monitored for side effects and any signs of cancer control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact